Commentary: How to Evaluate the Opportunity of Indication-Based Drug Contracting
Precision for Value’s Jeremy Schafer discusses the concept of indication-based drug contracting and how it could represent a new frontier of manufacturer-payer agreements.
Commentary: Understanding Health Care’s Short-Termism Problem
Precision’s Chief Scientific Officer Amitabh Chandra and PHE founding partner Dana Goldman address health care’s Short-Termism problem in their latest article for the Harvard Business Review.
Sandoz’ Filgrastim Biosimilar Is Now on the US Market – Pharmaceutical Commerce Magazine
Precision for Medicine’s Larry Blandford quoted in an article from Pharmaceutical Commerce magazine on a new biosimilar product from Novartis’ Sandoz unit called Zarxio.
Commentary: World Returns in Health Care Will Drive How Long You Live, But Your Country Will Stand in Your Way
Tomas Philipson’s latest Forbes.com Op-Ed examines how international linkages between health care economies will affect how long you and your kids will live.
Precision’s MacEwan Participates in The Network for Excellence in Health Innovation (NEHI) “On Call” Series
The Network for Excellence in Health Innovation (NEHI) held a special forum on August 19th, focusing on better use of medicines in diabetes, featuring the recent study and ADA presentation by Precision’s Joanna MacEwan. She discussed her recent work and fielded questions from the NEHI membership– exploring the implications of new research on the use of diabetes medications and what it means for health care delivery reform, insurance benefit design, changes in health care payment and other critical policy issues.